13.46
-0.05 (-0.37%)
| Previous Close | 13.51 |
| Open | 13.50 |
| Volume | 436,472 |
| Avg. Volume (3M) | 1,211,719 |
| Market Cap | 677,573,696 |
| Price / Book | 8.35 |
| 52 Weeks Range | |
| Earnings Date | 4 Sep 2025 |
| Diluted EPS (TTM) | -3.69 |
| Total Debt/Equity (MRQ) | 3.98% |
| Current Ratio (MRQ) | 10.44 |
| Operating Cash Flow (TTM) | -127.65 M |
| Levered Free Cash Flow (TTM) | -72.82 M |
| Return on Assets (TTM) | -58.15% |
| Return on Equity (TTM) | -150.50% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | KalVista Pharmaceuticals, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -3.0 |
| Price Volatility | -1.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.10 |
|
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.47% |
| % Held by Institutions | 112.39% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 27.00 (JMP Securities, 100.59%) | Buy |
| 27.00 (HC Wainwright & Co., 100.59%) | Buy | |
| Median | 27.00 (100.59%) | |
| Low | 20.00 (Leerink Partners, 48.59%) | Buy |
| Average | 24.67 (83.28%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 14.84 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 11 Jul 2025 | 27.00 (100.59%) | Buy | 14.52 |
| 08 Jul 2025 | 27.00 (100.59%) | Buy | 14.95 | |
| JMP Securities | 08 Jul 2025 | 27.00 (100.59%) | Buy | 14.95 |
| Leerink Partners | 07 Jul 2025 | 20.00 (48.59%) | Buy | 15.06 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| AUDHYA PAUL K. | - | 12.99 | -2,336 | -30,345 |
| SWEENY NICOLE | - | 12.99 | -1,480 | -19,225 |
| YEA CHRISTOPHER | - | 12.99 | -1,954 | -25,382 |
| Aggregate Net Quantity | -5,770 | |||
| Aggregate Net Value ($) | -74,952 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 12.99 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| AUDHYA PAUL K. | Officer | 25 Aug 2025 | Sell (-) | 2,336 | 12.99 | 30,345 |
| YEA CHRISTOPHER | Officer | 25 Aug 2025 | Sell (-) | 1,954 | 12.99 | 25,382 |
| SWEENY NICOLE | Officer | 25 Aug 2025 | Sell (-) | 1,480 | 12.99 | 19,225 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |